Earlier, Moderna reiterated 2023 expected minimum COVID-19 vaccines sales of approximately $5B from confirmed Advance Purchase Agreements and 2022 contract deferrals. In other news, Moderna said the mRNA-1010 Southern Hemisphere immunogenicity study in adults is fully enrolled, with a data readout expected in 1Q23, and the mRNA-1010 Northern Hemisphere efficacy study in older adults is fully enrolled, with the data readout that could occur this winter depending upon cases accrued in the study and vaccine efficacy. Moderna also said that the Phase 3 RSV study of has now accrued the cases required to complete the first interim efficacy analysis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MRNA:
- Moderna (NASDAQ:MRNA) Set to Match Pfizer’s Price for COVID Vaccine
- Moderna announces updates on mRNA pipeline
- CTMX Surges after Announcing MRNA Collaboration
- Morgan Stanley sees Moderna’s phase 3 RSV vaccine data as catalyst-driven idea
- CytomX Therapeutics updates business, announces 2023 relationship with Moderna